Company Announcements

Publication of Base Prospectus

Source: RNS
RNS Number : 9235Y
GlaxoSmithKline Capital PLC
09 September 2022

Issued: 9 September 2022, London UK


GlaxoSmithKline Capital plc Publication of Base Prospectus




GlaxoSmithKline Capital plc today announced that the following base prospectus dated 7 September 2022 has been approved by the Financial Conduct Authority and is available for viewing:

GSK plc, GlaxoSmithKline Capital plc, GSK Capital BV and GSK Capital KK £20,000,000,000 Euro Medium Term Note Programme

Copies of the base prospectus and the documents incorporated by reference within it have been submitted to the UK Listing Authority's National Storage Mechanism (NSM) submission portal via the Electronic Submission System (ESS). The base prospectus will shortly be available for inspection at and can be downloaded from:

For further information, please contact:

Company Secretary
GSK plc
980 Great West Road
United Kingdom


UK Media enquiries:

Tim Foley

+44 (0) 20 8047 5502


European Analyst/Investor enquiries:

Nick Stone

James Dodwell

+44 7717 618 834

+44 7881 269 066





Please note that the information contained in the base prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the base prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the base prospectus is not addressed. Prior to relying on the information contained in the base prospectus you must ascertain from the base prospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirements.


About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at


Registered in England & Wales:

No. 2258699


Registered Office:

980 Great West Road

Brentford, Middlesex






This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.